APA (7th ed.) Citation

Wang, T., Cui, Z., Ou, Y., Lou, S., Chen, H., Zhu, C., . . . Zou, F. (2025). Post-marketing safety concerns with pirfenidone and nintedanib. Frontiers in Pharmacology, 16, . https://doi.org/10.3389/fphar.2025.1530697

Chicago Style (17th ed.) Citation

Wang, Tao, Zhiwei Cui, Yingyong Ou, Siyu Lou, Huayou Chen, Chengyu Zhu, Linmei Zhou, and Fan Zou. "Post-marketing Safety Concerns with Pirfenidone and Nintedanib." Frontiers in Pharmacology 16 (2025). https://doi.org/10.3389/fphar.2025.1530697.

MLA (9th ed.) Citation

Wang, Tao, et al. "Post-marketing Safety Concerns with Pirfenidone and Nintedanib." Frontiers in Pharmacology, vol. 16, 2025, https://doi.org/10.3389/fphar.2025.1530697.